首页> 外文期刊>Experimental and therapeutic medicine >A modified ultra-long pituitary downregulation protocol improved endometrial receptivity and clinical outcome for infertile patients with polycystic ovarian syndrome
【24h】

A modified ultra-long pituitary downregulation protocol improved endometrial receptivity and clinical outcome for infertile patients with polycystic ovarian syndrome

机译:改良的超长垂体下调方案改善了多囊卵巢综合征不育患者的子宫内膜容受性和临床结局

获取原文
获取原文并翻译 | 示例
       

摘要

There are currently various protocols for in vitro fertilization (IVF). For patients with polycystic ovarian syndrome (PCOS), an optimized protocol for the downregulation of pituitary follicle stimulating hormone and luteinizing hormone via gonadotropin-releasing hormone agonist (GnRHa) remains a challenge. In the present study, the primary endpoint of an ultra-long and a conventional long GnRHa protocol for intracytoplasmic sperm injection/IVF treatments of patients with PCOS was retrospectively compared. In the modified ultra-long protocol group, endometrial thickness, morphology, and blood flow were significantly improved, as compared with in the conventional long protocol group. Furthermore, the serum progestogen (P) concentrations and P/estrogen (E2) [(Px1,000/E2)] ratio on the day of human chorionic gonadotrophin administration were significantly decreased in the modified ultra-long downregulation group, whereas the pregnancy and implantation rates were significantly higher. There were no significant differences in the average number of obtained oocytes, good quality embryo rates, cancel rates, fertilization rates, abortion rates, serious ovarian hyperstimulation syndrome incidences, ectopic pregnancy rates or gonadotropin (Gn) dosages between the two groups. These results suggest that the modified ultra-long protocol plus human menopausal Gn medication may be superior to the conventional long protocol, and may lead to improved implantation and pregnancy outcomes for infertile patients with PCOS.
机译:当前有多种体外受精(IVF)方案。对于患有多囊卵巢综合征(PCOS)的患者,通过促性腺激素释放激素激动剂(GnRHa)下调垂体促卵泡激素和促黄体生成激素的最佳方案仍然是一个挑战。在本研究中,回顾性比较了PCOS患者胞浆内精子注射/ IVF治疗的超长和常规长GnRHa方案的主要终点。与常规的长方案组相比,改良的超长方案组的子宫内膜厚度,形态和血流显着改善。此外,改良超长下调组中人绒毛膜促性腺激素给药当天的血清孕激素(P)浓度和P /雌激素(E2)[(Px1,000 / E2)]比明显降低。植入率明显更高。两组之间获得的卵母细胞的平均数量,优质胚胎的发生率,消除率,受精率,流产率,严重的卵巢过度刺激综合征发生率,异位妊娠率或促性腺激素(Gn)剂量之间无显着差异。这些结果表明,改良的超长方案加上人类更年期的Gn药物可能优于常规的长方案,并且可能导致不育PCOS患者的植入和妊娠结局得到改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号